Publications
July 14, 2021
International Journal of Toxicology
Preclinical Safety Assessment and Toxicokinetics of Apitegromab, an Antibody Targeting Proforms of Myostatin for the Treatment of Muscle-Atrophying Disease
May 11, 2021
Advances in Therapy
A Randomized Phase 1 Safety, Pharmacokinetic and Pharmacodynamic Study of the Novel Myostatin Inhibitor Apitegromab (SRK-015): A Potential Treatment for Spinal Muscular Atrophy
March 22, 2021
International Journal of Toxicology
Nonclinical Development of SRK-181: An Anti-Latent TGFβ1 Monoclonal Antibody for the Treatment of Locally Advanced or Metastatic Solid Tumors
Posters
June 2021
Virtual 2021 7th Congress of the European Academy of Neurology (EAN)
Apitegromab, an Investigational Anti-proMyostatin Monoclonal Antibody for Spinal Muscular Atrophy: Phase 2 Results (Presentation)
June 2021
2021 American Society of Clinical Oncology (ASCO) Annual Meeting
First-in-Human Phase 1 Trial (DRAGON) of SRK-181: A Potential First-in-Class Selective Latent TGFβ1 Inhibitor, Alone or in Combination with Anti-PD-(L)1 Treatment in Patients with Advanced Solid Tumors
May 2021
16th International Congress on Neuromuscular Diseases (ICNMD 2021)
TOPAZ: Phase 2 Study Evaluating Efficacy and Safety of Apitegromab in Later-Onset Spinal Muscular Atrophy; An Interim Analysis